Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Single-armed Study Using Subject-specific Minimal Residual Disease Markers to Adopt Treatment After Allogeneic Stem Cell Transplantation for Subjects With Myelodysplastic Syndrome

NCT05788679 is registered in ClinicalTrials.gov with Karolinska University Hospital as lead sponsor.

NCT NCT05788679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05788679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Single-armed Study Using Subject-specific Minimal Residual Disease Markers to Adopt Treatment After Allogeneic Stem Cell Transplantation for Subjects With Myelodysplastic Syndrome
Lead sponsor
Karolinska University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 22, 2022
Completion date
December 31, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with myelodysplasia related disease and < 30% blasts, mixed myelodysplastic/myeloproliferative disease, myelodysplastic syndromes